68 related articles for article (PubMed ID: 25344863)
1. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.
Grabow S; Delbridge AR; Valente LJ; Strasser A
Blood; 2014 Dec; 124(26):3939-46. PubMed ID: 25368374
[TBL] [Abstract][Full Text] [Related]
2. Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment.
Ebrahimnia M; Alavi S; Vaezi H; Karamat Iradmousa M; Haeri A
EXCLI J; 2024; 23():143-179. PubMed ID: 38487087
[TBL] [Abstract][Full Text] [Related]
3. A promising nucleic acid therapy drug: DNAzymes and its delivery system.
Xiao L; Zhao Y; Yang M; Luan G; Du T; Deng S; Jia X
Front Mol Biosci; 2023; 10():1270101. PubMed ID: 37753371
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL DNAzymes promote radiosensitivity and chemosensitivity in colorectal cancer cells via enhancing apoptosis.
Yu Z; Guo J; Meng T; Ge L; Liu L; Wang H; Yang X
BMC Pharmacol Toxicol; 2022 Feb; 23(1):13. PubMed ID: 35123593
[TBL] [Abstract][Full Text] [Related]
5. DNAzymes, Novel Therapeutic Agents in Cancer Therapy: A Review of Concepts to Applications.
Thomas IBK; Gaminda KAP; Jayasinghe CD; Abeysinghe DT; Senthilnithy R
J Nucleic Acids; 2021; 2021():9365081. PubMed ID: 34760318
[TBL] [Abstract][Full Text] [Related]
6. Cell Survival Is Regulated via SOX9/BCL2L1 Axis in HCT-116 Colorectal Cancer Cell Line.
Lizárraga-Verdugo E; Ruiz-García E; López-Camarillo C; Bermúdez M; Avendaño-Félix M; Ramos-Payán R; Romero-Quintana G; Ayala-Ham A; Villegas-Mercado C; Pérez-Plasencia C; Aguilar-Medina M
J Oncol; 2020; 2020():5701527. PubMed ID: 32411238
[TBL] [Abstract][Full Text] [Related]
7. Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators.
Corigliano DM; Syed R; Messineo S; Lupia A; Patel R; Reddy CVR; Dubey PK; Colica C; Amato R; De Sarro G; Alcaro S; Indrasena A; Brunetti A
PeerJ; 2018; 6():e5386. PubMed ID: 30123711
[TBL] [Abstract][Full Text] [Related]
8. Pro-inflammatory effect of a traditional Chinese medicine formula with potent anti-cancer activity
Xia L; Plachynta M; Liu T; Xiao X; Song J; Li X; Zhang M; Yao Y; Luo H; Hao X; Ben-David Y
Mol Clin Oncol; 2016 Dec; 5(6):717-723. PubMed ID: 28101351
[TBL] [Abstract][Full Text] [Related]
9. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.
Guest ST; Kratche ZR; Irish JC; Wilson RC; Haddad R; Gray JW; Garrett-Mayer E; Ethier SP
Oncotarget; 2016 Jun; 7(24):36138-36153. PubMed ID: 27153554
[TBL] [Abstract][Full Text] [Related]
10. Deoxyribozymes as Catalytic Nanotherapeutic Agents.
Khachigian LM
Cancer Res; 2019 Mar; 79(5):879-888. PubMed ID: 30760521
[TBL] [Abstract][Full Text] [Related]
11. Bcl-x
Beaumatin F; El Dhaybi M; Bobo C; Verdier M; Priault M
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1734-1745. PubMed ID: 28645514
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme.
Yu X; Yang L; Cairns MJ; Dass C; Saravolac E; Li X; Sun LQ
Oncotarget; 2014 Oct; 5(19):9039-48. PubMed ID: 25344863
[TBL] [Abstract][Full Text] [Related]
13. Selection and antitumor activity of anti-Bcl-2 DNAzymes.
Yang X; Li Z; Zhang L; He J; Sun LQ
Biochem Biophys Res Commun; 2016 Oct; 479(3):544-550. PubMed ID: 27666476
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
15. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
